Is Retatrutide the Same as Tirzepatide?

No, retatrutide is not the same as tirzepatide. Both are injectable drugs developed by Eli Lilly and studied for type 2 diabetes and weight loss, but they activate different hormone receptors and sit in very different stages of regulatory review. Tirzepatide is FDA-approved and sold as Mounjaro and Zepbound, while retatrutide remains investigational and cannot be prescribed anywhere in the United States.

Retatrutide vs Tirzepatide at a Glance

Receptor Targets: The Core Difference Between Retatrutide and Mounjaro

The difference between retatrutide and Mounjaro comes down to how many hormone receptors each drug activates. Tirzepatide is a dual agonist, meaning it mimics two gut hormones: GIP and GLP-1. Retatrutide is a triple agonist that adds the glucagon receptor to that list.

That third receptor is the real scientific dividing line. Glucagon signaling can increase energy expenditure and fat oxidation, which is one reason researchers are interested in triple agonism for obesity. Glucagon also raises blood glucose on its own, so the GLP-1 and GIP activity in retatrutide is what keeps the formula balanced.

Activating more receptors does not automatically make a drug stronger or safer. Scientists are still working out whether triple agonism produces meaningfully better outcomes than dual agonism, and no head-to-head trial has settled that question.

FDA Approval: One Is Prescribed, the Other Is Not

Tirzepatide received FDA approval in May 2022 as Mounjaro for type 2 diabetes, then again in November 2023 as Zepbound for chronic weight management. It is available by prescription nationwide, with brand-name pens as well as compounded versions in limited circumstances.

Retatrutide has no FDA approval for any indication. Eli Lilly is running the phase 3 TRIUMPH program, and results are expected to inform a future regulatory filing. Until that happens, retatrutide is not FDA-approved for human use in the United States, and it is not stocked by licensed pharmacies.

This is why people weighing retatrutide or Mounjaro are really comparing a triple agonist that does not exist on the market yet with a dual agonist they can actually fill at a pharmacy today.

Retatrutide vs Tirzepatide: Which Is Better?

That exact question — retatrutide vs tirzepatide which is better — is one of the most common ways people search this topic, and the honest answer is that nobody knows yet. There is no published head-to-head clinical trial comparing the two drugs in the same patients.

What exists instead are separate trials with different designs, durations, and populations:

• Retatrutide phase 2: roughly 24% average weight loss at 48 weeks with the 12 mg weekly dose.
• Tirzepatide (SURMOUNT-1): roughly 21% average weight loss at 72 weeks with the 15 mg weekly dose.

Retatrutide's numbers come from a shorter trial, which makes a direct comparison misleading. Phase 3 results will give a much clearer picture of how the two drugs stack up.

Dosing and Side Effects

Tirzepatide dosing starts at 2.5 mg once weekly and is stepped up gradually to a maximum of 15 mg weekly. Retatrutide doses in trials have ranged from 1 mg to 12 mg weekly, with some phase 3 arms testing higher amounts. Neither drug is meant to be started at a full dose.

Both drugs share a similar side effect profile, largely driven by how they slow digestion:

• Nausea, vomiting, and diarrhea
• Constipation and reduced appetite
• Injection site reactions
• Possible gallbladder problems and pancreatitis, which are rare but serious

Retatrutide trials have also reported a dose-related increase in heart rate that researchers continue to monitor. Anyone using either drug needs medical supervision, especially if they take diabetes medication, have a history of pancreatitis, or are pregnant or planning to become pregnant.

Don't Confuse These With Other Peptides and GLP-1 Drugs

Search traffic around this topic is full of lookalike questions. People ask is glp rt the same as retatrutide, and the answer is that "GLP-RT" is not a recognized drug name — it appears to be shorthand or a mislabel used by some online vendors rather than a synonym for retatrutide.

Similarly, is tirzepatide the same as ozempic has a clear answer: no. Ozempic is semaglutide, a GLP-1-only agonist made by Novo Nordisk, while tirzepatide is a dual GIP/GLP-1 agonist made by Eli Lilly.

The confusion is not limited to weight-loss drugs. is cjc-1295 the same as ipamorelin also comes up often, and those are two distinct research peptides that are sometimes discussed in the same forum threads but are not interchangeable.

Safety and Sourcing: What to Watch For

Because retatrutide is not approved, any product sold online under that name is unregulated. Vials labeled "retatrutide" may contain the wrong peptide, an unknown dose, or contaminants, and there is no pharmacy or regulator checking the contents.

People who handle research peptides often ask is reconstitution solution the same as bac water — they are not identical. Bacteriostatic water contains a preservative that limits bacterial growth, while plain reconstitution solution may not, so mixing up the two affects sterility, not just concentration.

If you are interested in a GLP-1 or dual-agonist medication, talk with a licensed healthcare professional about approved options such as Mounjaro or Zepbound, insurance coverage, and whether a compounded version is legally available in your state. Do not self-dose with unverified product.

The Bottom Line

Retatrutide and tirzepatide are not the same drug, even though the same company developed both. Tirzepatide is an approved dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound, and retatrutide is an investigational triple agonist still working through phase 3 trials. For anyone deciding what to take today, the real choice is between one approved prescription medication and one that is not available at all.